Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

@inproceedings{Mayer2014AntiIP10A,
  title={Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study},
  author={Lloyd Hitoshi Mayer and W J Sandborn and Yuriy Stepanov and Karel Geboes and Robert Hardi and Michael Jay Yellin and Xiaolu Tao and Li An Xu and Luisa Salter-Cid and Sheila Gujrathi and Richard Aranda and Allison Y Luo},
  booktitle={Gut},
  year={2014}
}
OBJECTIVE Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients with ulcerative colitis (UC). This phase II study assessed the efficacy and safety of BMS-936557, a fully human, monoclonal antibody to IP-10, in the treatment of moderately-to-severely active UC. DESIGN In this 8-week, phase II, double-blind, multicentre, randomised… CONTINUE READING